Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;120(6):10239-10247.
doi: 10.1002/jcb.28308. Epub 2019 Jan 4.

Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice

Affiliations

Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice

Mingyu Zhang et al. J Cell Biochem. 2019 Jun.

Abstract

The expression of programmed death ligand-1 (PD-L1) in tumor has been used as a biomarker to predict the anti-PD-L1 immunotherapy response. To develop a noninvasive imaging technique to monitor the dynamic changes in PD-L1 expression in colorectal cancer (CRC), we labeled an anti-PD-L1 monoclonal antibody with near-infrared (NIR) dye and tested the ability of the NIR-PD-L1-mAb probe to monitor the PD-L1 expression in CRC-xenografted mice by performing optical imaging. Consistent with the expression levels of PD-L1 protein in three CRC cell lines in vitro by flow cytometry and Western blot analyses, our in vivo imaging showed the highest fluorescence signal of the xenografted tumors in mice bearing SW620 CRC cells, followed by tumors derived from SW480 and HCT8 cell lines. We detected the highest fluorescent intensity of the tumor at 120 hours after injection of NIR-PD-L1-mAb. The highest fluorescence intensity was seen in the tumor, followed by the spleen and the liver in SW620 xenografted mice. In SW480 and HCT8 xenografted mice, however, the highest fluorescent signals were detected in the spleen, followed by the liver and the tumor. Our findings indicate that SW620 cells express a higher level of PD-L1, and the NIR-PD-L1-mAb binding to PD-L1 on the surface of CRC cells was specific. The technique was safe and could provide valuable information on PD-L1 expression of the tumor for development of a therapeutic strategy of personized targeted immunotherapies as well as treatment response of patients with CRC.

Keywords: colorectal cancer; immunotherapy; noninvasive imaging; optical imaging; programmed death ligand-1/programmed death ligand-1 checkpoint.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1
NIR‐PD‐L1‐mAb has higher affinity binding to PD‐L1 in SW620 cells than SW480 and HCT8 cell lines. Binding affinity of anti‐PD‐L1 monoclonal antibody to the surface PD‐L1 was analyzed by FACS. A, Colorized histograms represent anti‐human PD‐L1 antibody binding to SW620, SW480 and HCT8 cell lines as indicated. B, Quantification of fluorescent intensity of SW620, SW480, and HCT8 cell lines detected by FACS. Data are expressed as the mean ± standard deviation and the significance of the value is indicated by asterisk, ***P   0.001 (n = 3). NIR, near‐infrared; PD‐L1, programmed death ligand‐1
Figure 2
Figure 2
Comparison of PD‐L1 protein expression levels between SW620, SW480, and HCT8 cells in vitro. A, PD‐L1 expression in SW620, SW480, and HCT8 cells measured by the Western blot. B, Quantification of Western blot analyses. Data are expressed as the mean ± standard deviation and the significance of the value is indicated by an asterisk, ***P   0.001, **P   0.01 (n = 3). PD‐L1, programmed death ligand‐1
Figure 3
Figure 3
NIR‐PD‐L1‐mAb specifically binds to PD‐L1 in human colorectal cancer xenografted mice. A, Optical images in SW620, SW480, and HCT8 grafted mice at different time‐points. B, Quantitative fluorescent intensity of optical imaging regions of interest (ROIs) of tumor to background at 24, 48, 72, and 120 hours, respectively after injection of NIR‐PD‐L1‐mAb (n = 3). Data are expressed as the mean ± standard deviation of the fluorescence intensity ratio of tumor to background. The significance of the value is indicated by an asterisk, ***P   0.001. NIR, near‐infrared; PD‐L1, programmed death ligand‐1
Figure 4
Figure 4
Ex vivo optical biodistribution at 120 hours after injection of NIR‐PD‐L1‐mAb in SW620, SW480, and HCT8 xenograft models. A, B, Optical biodistribution image and corresponding quantitative data of SW620 grafted mice. C, D, Optical biodistribution image and corresponding quantitative data of SW480 grafted mice. E, F, Optical biodistribution image and corresponding quantitative data of HCT8 grafted mice. G, Histograms of biodistribution fluorescent accumulation in SW620, SW480, and HCT8 grafted mice, respectively. Data are expressed as the mean ± standard deviation of the fluorescent intensity ratio of tumor to background. The significance of the value is indicated by an asterisk, ***P   0.001 (n = 3) by one‐way ANOVA. ANOVA, analysis of variance; NIR, near‐infrared; PD‐L1, programmed death ligand‐1

Similar articles

Cited by

References

    1. Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA‐4 and PD‐1, the generation Z of negative checkpoint regulators. Front Immunol. 2015;6:418 10.3389/fimmu.2015.00418 - DOI - PMC - PubMed
    1. Honda T, Egen JG, Lämmermann T, Kastenmüller W, Torabi‐Parizi P, Germain RN. Tuning of antigen sensitivity by T cell receptor‐dependent negative feedback controls T cell effector function in inflamed tissues. Immunity. 2014;40(2):235‐247. 10.1016/j.immuni.2013.11.017 - DOI - PMC - PubMed
    1. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450‐461. 10.1016/j.ccell.2015.03.001 - DOI - PMC - PubMed
    1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immuno‐surveillance to tumor escape. Mat Immunol. 2002;3:991‐998. - PubMed
    1. Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour‐specific mutant antigens. Nature. 2014;515(7528):577‐581. 10.1038/nature13988 - DOI - PMC - PubMed

Publication types

MeSH terms